Mahajan Imaging & Labs, a prominent diagnostic chain in India, has unveiled an Artificial Intelligence (AI)-integrated blood biomarker test designed for the early detection of Alzheimer's disease. This innovative diagnostic method, utilizing the pTAU/Aβ1-42 (or pTAU217/β-Amyloid1-42) blood biomarker test, has received approvals from both the US Food and Drug Administration (FDA) and India's Central Drugs Standard Control Organisation (CDSCO), making it a significant advancement in Indian clinical practice. The introduction of this test was formally announced and discussed during a scientific symposium held in Gurugram on January 19th, 2026, bringing together leading neurologists and imaging specialists. Historically, Alzheimer's diagnosis in India has been challenged by the limited availability and high cost of traditional methods such as amyloid PET imaging, which can cost up to Rs 2 lakh, and invasive cerebrospinal fluid (CSF) testing. This new AI-enabled blood test offers a less invasive, more affordable, and accessible alternative, shifting the diagnostic approach from symptom-based assessments to a biology-first diagnosis. It allows clinicians to identify Alzheimer's-related biological changes much earlier, even before severe cognitive symptoms like memory loss become apparent. The integration of blood biomarkers with advanced imaging techniques like PET and MRI is considered a game-changer, not only for early diagnosis but also for monitoring patients undergoing newer treatments. With over 8.8 million Indians aged 60 and above currently living with dementia, a number projected to almost double by 2036, the need for scalable and early detection tools is critical. This development is expected to significantly strengthen India's healthcare system's ability to respond proactively to the growing dementia crisis, aligning Indian diagnostics with evolving global standards for Alzheimer's care.